Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Revvity Inc (RVTY) vs Vir Biotechnology Inc. Common Stock (VIR) Price & Performance

Revvity IncTrade
Vir Biotechnology Inc. Common StockTrade

Price performance (Past 24H)

Key statistics

Revvity Inc vs Vir Biotechnology Inc. Common Stock — how do they compare? Revvity Inc trades at $151.84 (market cap $17.30B), while Vir Biotechnology Inc. Common Stock trades at $10.2 (market cap $1.80B). The key difference: Revvity Inc is far larger — about 9.6× Vir Biotechnology Inc. Common Stock's market cap, and Revvity Inc pays a 0.18% dividend while Vir Biotechnology Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Revvity Inc for 13 Days and Vir Biotechnology Inc. Common Stock for 0 Days on average.

RVTYVIR
Market Cap
$17.30B$1.80B
Volume
1,387,5881,782,836
Sector
HealthHealth
52-Week High
$157.36$11.78
52-Week Low
$82.26$5.12
Typical Hold Time
13 Days0 Days
Enterprise Value
$19.62B$1.36B
Dividend Yield
0.18%—

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Revvity Inc

RVTY trades at $155.08, down 0.34% on the day but near its 52-week high of $158.28. The stock shows strong technical momentum with bullish moving averages and has consistently beaten earnings estimates in recent quarters. Recent developments include the launch of a new diabetes detection kit in Europe and the acquisition of Human Cell Design to expand metabolic disease research capabilities. The company maintains solid profitability with 54.98% gross margins and positive cash flow trends.

RVTY presents growth potential through diagnostic expansion and AI-driven demand, though premium valuation metrics (P/E 74.56) require careful consideration. Near-term catalysts include Q3 earnings on November 3, 2026, while risks involve China market pressures and margin compression. Analyst consensus leans bullish with 52% buy ratings and a $132.13 price target, suggesting potential downside from current levels despite positive momentum.

Vir Biotechnology Inc. Common Stock

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

RVTY

No sentiment data available yet.

VIR
51% Buy49% Sell
Avg holding period · 0 Days

About Revvity Inc

Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.

Read more on RVTY →

About Vir Biotechnology Inc. Common Stock

Vir Biotechnology, Inc. is a US clinical-stage biopharmaceutical company that develops monoclonal antibody-based medicines to treat and prevent serious infectious diseases.

Read more on VIR →